Q1 2020 EPS Estimates for Amedisys Inc Lowered by Analyst (NASDAQ:AMED)

Amedisys Inc (NASDAQ:AMED) – Research analysts at William Blair cut their Q1 2020 earnings estimates for shares of Amedisys in a note issued to investors on Friday, November 15th. William Blair analyst M. Larew now forecasts that the health services provider will post earnings of $1.12 per share for the quarter, down from their prior estimate of $1.13. William Blair also issued estimates for Amedisys’ Q3 2020 earnings at $1.20 EPS, Q4 2020 earnings at $1.25 EPS and FY2020 earnings at $4.78 EPS.

Several other brokerages have also commented on AMED. BidaskClub raised shares of Amedisys from a “buy” rating to a “strong-buy” rating in a research report on Friday, July 26th. Robert W. Baird raised shares of Amedisys from a “neutral” rating to an “outperform” rating and lifted their price objective for the stock from $140.00 to $160.00 in a research report on Friday, November 1st. UBS Group lifted their price objective on shares of Amedisys from $144.00 to $154.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. Royal Bank of Canada lifted their price objective on shares of Amedisys to $150.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. Finally, Barclays lifted their price objective on shares of Amedisys from $120.00 to $125.00 and gave the stock an “equal weight” rating in a research report on Monday, August 5th. Six investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $145.36.

Amedisys stock opened at $152.85 on Monday. The stock has a market cap of $4.88 billion, a PE ratio of 42.11, a price-to-earnings-growth ratio of 2.09 and a beta of 1.38. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.95 and a current ratio of 0.95. Amedisys has a fifty-two week low of $103.76 and a fifty-two week high of $154.14. The firm’s 50-day simple moving average is $135.57 and its 200 day simple moving average is $127.24.

Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Tuesday, October 29th. The health services provider reported $1.15 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.25. Amedisys had a net margin of 6.70% and a return on equity of 26.53%. The business had revenue of $494.63 million for the quarter, compared to analysts’ expectations of $494.14 million. During the same period in the previous year, the company earned $0.95 earnings per share. The firm’s revenue for the quarter was up 18.5% compared to the same quarter last year.

A number of hedge funds have recently added to or reduced their stakes in the business. Advisory Services Network LLC boosted its stake in shares of Amedisys by 7.6% in the 2nd quarter. Advisory Services Network LLC now owns 1,098 shares of the health services provider’s stock valued at $133,000 after purchasing an additional 78 shares in the last quarter. LS Investment Advisors LLC raised its holdings in Amedisys by 3.1% during the 3rd quarter. LS Investment Advisors LLC now owns 3,004 shares of the health services provider’s stock valued at $394,000 after buying an additional 90 shares during the last quarter. Oakbrook Investments LLC raised its holdings in Amedisys by 4.8% during the 3rd quarter. Oakbrook Investments LLC now owns 2,200 shares of the health services provider’s stock valued at $288,000 after buying an additional 100 shares during the last quarter. Financial Enhancement Group LLC raised its holdings in Amedisys by 17.8% during the 2nd quarter. Financial Enhancement Group LLC now owns 855 shares of the health services provider’s stock valued at $104,000 after buying an additional 129 shares during the last quarter. Finally, NEXT Financial Group Inc raised its holdings in Amedisys by 19.8% during the 3rd quarter. NEXT Financial Group Inc now owns 810 shares of the health services provider’s stock valued at $106,000 after buying an additional 134 shares during the last quarter. 87.59% of the stock is owned by institutional investors and hedge funds.

In related news, Director Donald A. Washburn sold 8,667 shares of the company’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $149.96, for a total transaction of $1,299,703.32. Following the sale, the director now owns 36,698 shares of the company’s stock, valued at approximately $5,503,232.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jake L. Netterville sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $135.64, for a total transaction of $135,640.00. Following the sale, the director now directly owns 72,700 shares in the company, valued at approximately $9,861,028. The disclosure for this sale can be found here. Insiders have sold a total of 18,407 shares of company stock worth $2,694,756 in the last ninety days. 2.90% of the stock is currently owned by insiders.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

See Also: Total Return

Earnings History and Estimates for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.